Botox Spasticity denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for botox spasticity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies OnabotulinumtoxinA (Botox) for Spasticity as "Duplicate Therapy" — and How to Appeal

A duplicate-therapy denial means Humana's records show that the patient is already receiving another treatment it considers therapeutically equivalent or overlapping with onabotulinumtoxinA (Botox) for spasticity management. Common triggers include concurrent claims for another botulinum toxin product, an oral antispasticity agent, or a neurostimulation-based therapy that Humana's policy categorizes as addressing the same clinical need.

These denials are frequently overturned because spasticity management is inherently multimodal. Botox injections target focal muscle groups and work by a local mechanism that is distinct from the systemic or central mechanisms of oral agents. A well-documented appeal that explains the clinical rationale for combination treatment — supported by the prescribing physiatrist or neurologist — typically succeeds.

## Federal Appeal Framework

Under ACA §2719, most non-grandfathered plans must offer internal appeal followed by independent external review by an Independent Review Organization (IRO). ERISA §503 governs full-and-fair review for self-funded employer plans. The external review window is generally open for approximately four months after the final internal denial. If spasticity is causing rapid functional decline or pain, request expedited review, which requires a decision within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's denial letter and its published coverage policy for botulinum toxin in spasticity. Identify exactly which concurrent therapy triggered the duplicate-therapy flag. 2. File a Level 1 internal appeal within the deadline on the denial notice. Ask the prescriber to address each policy criterion in writing. 3. If denied at Level 1, file a Level 2 appeal or proceed to IRO external review. 4. Request the specific clinical reviewer's rationale if not provided — you are entitled to it under ERISA and ACA rules.

## Documentation to Gather

• Diagnosis confirmation: neurologist or physiatrist notes confirming the underlying condition (e.g., stroke, MS, cerebral palsy, spinal cord injury) and the affected muscle groups
• Prior treatment history: records for each concurrent or prior therapy, including dates started, doses, and documented outcomes — with emphasis on why each addresses a different aspect of the patient's spasticity
• Clinical severity per the chart: functional assessments, spasticity scales recorded at clinic visits, and documentation of pain or caregiver burden
• Prescriber medical-necessity letter explaining the distinct mechanism and focal targeting of botulinum toxin compared to the therapy Humana flagged as duplicative
• Relevant society guideline reference: note the applicable guideline organization (e.g., American Academy of Neurology, American Academy of Physical Medicine and Rehabilitation) that supports multimodal spasticity management — without citing specific numbers or trial data

## Criteria-Mapping Structure

For each element of Humana's duplicate-therapy policy, provide a direct answer from the clinical record:

| Humana Policy Requirement | Chart Evidence | |---|---| | Identify the therapy Humana considers duplicative | [Name the flagged concurrent treatment] | | Demonstrate distinct mechanism or clinical target | [Prescriber explanation of focal vs. systemic action] | | Document clinical necessity for combination approach | [Functional assessment showing residual focal spasticity despite other treatment] | | Prior trial of alternative(s) with documented outcomes | [Dates and outcomes of prior oral or other agents] |